ALNY Stock Alnylam Pharmaceuticals, Inc.
BUY US · NasdaqGSEstablished RNA platform, strong momentum, and visible pipeline catalysts support quality growth.
Future value: $368.70 (+61.95%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Positive momentum and durable platform execution.
- ▾Below 50-day MA (-4.76%)
- ▾Near 52-week low (10.4% of range)
- ▸~62% upside to price target
Is ALNY a buy right now?
Trend: ALNY is trading below the 50-day average (-4.76%), RSI 52 — neutral momentum, with a 3-month return of -21.06%.
Valuation & quality: Alnylam Pharmaceuticals, Inc. trades on a trailing P/E of 38.4, forward P/E 18.4, PEG 0.29, price-to-book 22.48; fundamentals show net margin 16.1%, return on equity 96.6%, revenue growth 66.9% year on year.
Analyst consensus: 27 analysts have a mean 12-month price target of $367.78 (+61.5% vs the last close; range $250.00 – $536.00), consensus rating “buy”.
Our screen: BUY (score 2) — Established RNA platform, strong momentum, and visible pipeline catalysts support quality growth.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -0.60% | -6.50% | -2.40% | -0.30% | -31.70% | +17.10% | +2.50% | -7.70% |
Fundamentals
Analyst price target
Technical signals
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Sector: Healthcare · Industry: Biotechnology · United States · 2,500 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.